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Introduction. Treatment of locally advanced squamous cell carcinomas of head and neck (LA-SCCHN) is evolving. The aim of the
present study is to analyze clinical outcomes and toxicity in far advanced cancer with combined triple therapy of chemotherapy
(CHT), hyperfractionated radiotherapy (HF-RT) and cetuximab (CTX).
Material and methods. 27 newly diagnosed LA-SCCHN patients were included between September 2009 and December 2012. RT
consisted in HF-RT: 1.15Gy/fraction, BID, 5 days/week, 7 weeks. Carboplatin was administered 5mg/m2 before each fraction of
RT. Cetuximab was administered 400mg/m2 one week before RT-CTH and then 250mg/m2 weekly while RT-CHT. Patients were
evaluated for response two months after completing treatment. Toxicity was scored by CTCA 4.0 criteria.
Results. Median age was 51.6 years (44–65), 85% were males. All patients were stage IV. Tumors were located mainly in oropharynx
(47%) and hypopharynx (30%). One patient were excluded due to an allergic reaction in the ﬁrst infusion of CTX and 26 patients
(96%) received the completeplanned treatment andwere evaluated for response.All patients achievedobjective response, 22 (85%)
had a complete response (CR) and 4 a partial response. Two patients with CR had a locorregional relapse (one with syncronous
pulmonar metastasis). 3 out of 6 patients with progressive disease were eligible either for surgical rescue (1) or CHT (2). With a
median follow-up of 16.7 months (5–39), 23 of 26 patients were alive, with an actuarial survival at 3 years of 88.5%. Massive nodal
invasion N3 was a strong prognostic factor for survival (p<0.007). Among the 26 evaluable patients for toxicity, 85% had grade 3
radiodermitis and 82% grade 3 mucositis. Acneiform rash was grade 3 in 78% of the patients.
Conclusion. This is a feasible treatment in patients with an optimal Karnofsky Status and far advanced SSCHN obtaining an
immediate response in all cases, with an acceptable tolerance and encouraging overall survival ﬁgures.
http://dx.doi.org/10.1016/j.rpor.2013.03.266
Hypopharyngeal cancer and organ preservation
L. Gutierrez Bayard, M. Salas Buzón, L. de Ingunza Barón, E. Gonzalez Calvo
Hospital Universitario Puerta del Mar, Oncología Radioterápica
Introduction. Hypopharyngeal cancer accounts for about a quarter of all malignancies of the head and neck. The diagnosis in
advanced stages and high incidence of early metastases, place overall survival rates after ﬁve years on ﬁgures from 30% to 35%.
No treatment by itself, surgery at different options, radiotherapy and/or chemotherapy, offers a clear advantage in survival.
Purpose. A descriptive study of 83 patients with hypopharyngeal cancer treated with radiotherapy (initial stage) or concomi-
tant radiotherapy and chemotherapy (neoadyuvant chemotherapy and radio-chemotherapy, or radiotherapy and concurrent
chemotherapy) as a ﬁrst therapeutic option in the period from January 2008 to June 2012.
Methods. 68% of patients were smokers and 76.5% alcohol at the time of diagnosis. The symptom of initial consultation was the
presence of a lateral adenopathy. In 75% of patients followed by odynophagia. With regard to staging the initial stages were 2.6%
and 97% advanced stage with 78% stage IV. In 7.7% had local or locoregional surgical salvage for persistent or recurrent tumor.
Results. Of all patients 64% died of distant metastases or locoregional relapse. Increased risk of locoregional recurrence or distant
metastasis is located in the ﬁrst two years, in the ﬁrst year was detected in 63% of patients and the second years was detected
in 37% of patients.
Conclusions. The improvement in overall survival in carcinoma of the hypopharynx is still present a challenge for professionals.
The initial therapeutic option will depend on the patient, tumor stage, status performance, the experience of professionals and
treatment facilities available. Treatmentdecisions should bedecidedbyaCommitteeHeadandNeckCancer andmultidisciplinary
therapy that will be essential in the comprehensive management of the tumor.
http://dx.doi.org/10.1016/j.rpor.2013.03.267
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Radiotherapy, with or without chemotherapy, is the standard treatment of nasopharyngeal cancer. IMRT allows to give higher
dose to the PTV, and lower dose to adjacent organs. We reviewed our experience with this group of patients. We wished to assess
the local control (partial or total response on CT or MRI evaluation) and incidence of late side-effects incidence. Between February
2007and March 2012, we treated 16 nasopharyngeal cancer patients with skull base inﬁltration (T4 stage) with IMRT. Eleven were
males and ﬁve females, median age 65 (range 15–81). Thirteen patients had undifferentiated carcinoma (81%) and 3 squamous
carcinoma (19%). Six patientswere treatedwith forward IMRT: 72–74Gyof total dose, 1.8Gyper day, 40 days. Remaining 10 patients
(62%) were treated with inverse planiﬁcation IMRT: 70–73Gy (m=72) 2.20–2.35Gy/fraction (m=2.29) 30–32 fractions (m=30.2). Six
patients received neoadjuvant chemotherapy (37%), and 14 concomitant and adjuvant chemotherapy (87%) Median follow-up is
